Cixutumumab

Kevin P. McKian; Paul Haluska

doi:10.1517/13543780903055049

Cixutumumab

Kevin P. McKian, Paul Haluska

Oncology

Research output: Contribution to journal › Review article › peer-review

51 Scopus citations

Abstract

The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

Original language	English (US)
Pages (from-to)	1025-1033
Number of pages	9
Journal	Expert Opinion on Investigational Drugs
Volume	18
Issue number	7
DOIs	https://doi.org/10.1517/13543780903055049
State	Published - Jul 2009

Keywords

Cixutumumab
IGF-1R
IMC-A12
Monoclonal antibody

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/13543780903055049

Cite this

@article{ebb91ddae85a497ea81f5b2ec7e727f2,

title = "Cixutumumab",

abstract = "The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.",

keywords = "Cixutumumab, IGF-1R, IMC-A12, Monoclonal antibody",

author = "McKian, {Kevin P.} and Paul Haluska",

year = "2009",

month = jul,

doi = "10.1517/13543780903055049",

language = "English (US)",

volume = "18",

pages = "1025--1033",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Cixutumumab

AU - McKian, Kevin P.

AU - Haluska, Paul

PY - 2009/7

Y1 - 2009/7

N2 - The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

AB - The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

KW - Cixutumumab

KW - IGF-1R

KW - IMC-A12

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=67650436410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650436410&partnerID=8YFLogxK

U2 - 10.1517/13543780903055049

DO - 10.1517/13543780903055049

M3 - Review article

C2 - 19548856

AN - SCOPUS:67650436410

SN - 1354-3784

VL - 18

SP - 1025

EP - 1033

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 7

ER -

Cixutumumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this